Sung H. Ferlay J. Siegel R.L. et al.

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

CA Cancer J Clin. 71: 209-249Cancer Genome Atlas Research N, Analysis Working Group Asan U. Agency BCC et al.

Integrated genomic characterization of oesophageal carcinoma.

Nature. 541: 169-175Hato S.V. Khong A. de Vries I.J. et al.

Molecular pathways: the immunogenic effects of platinum-based chemotherapeutics.

Clin Cancer Res. 20: 2831-2837Janjigian Y.Y. Shitara K. Moehler M. et al.

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.

Lancet. 398: 27-40Shitara K. Ajani J.A. Moehler M. et al.

Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer.

Nature. 603: 942-948Janjigian Y.Y. Bendell J. Calvo E. et al.

CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer.

J Clin Oncol. 36: 2836-2844Sun J.M. Shen L. Shah M.A. et al.

Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.

Lancet. 398: 759-771Xu J. Jiang H. Pan Y. et al.

Sintilimab plus chemotherapy (chemo) versus chemo as first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-16): First results of a randomized, double-blind, phase III study.

Ann Oncol. 32: S1331Boku N. Ryu M.H. Oh D-.Y. et al.

Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrence gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study.

Ann Oncol. 31: S1142-S1215Zhao J.J. Yap D.W.T. Chan Y.H. et al.

Low Programmed Death-Ligand 1-Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma.

J Clin Oncol. 40: 392-402Pietrantonio F. Miceli R. Raimondi A. et al.

Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer.

J Clin Oncol. 37: 3392-3400Andre T. Tougeron D. Piessen G. et al.

Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in patients (pts) with localized microsatellite instability-high (MSI)/mismatch repair deficient (dMMR) oeso-gastric adenocarcinoma (OGA): The GERCOR NEONIPIGA phase II study.

J Clin Oncol. 40: 244Bonneville R. Krook M.A. Kautto E.A. et al.

Landscape of Microsatellite Instability Across 39 Cancer Types.

JCO Precis Oncol. 2017Chao J. Fuchs C.S. Shitara K. et al.

Assessment of pembrolizumab therapy for the treatment of microsatellite instability-high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials.

JAMA Oncol. 7: 895-902Janjigian Y.Y. Sanchez-Vega F. Jonsson P. et al.

Genetic predictors of response to systemic therapy in esophagogastric cancer.

Cancer Discov. 8: 49-58Shitara K. Van Cutsem E. Bang Y.J. et al.

Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial.

JAMA Oncol. 6: 1571-1580Fuchs C.S. Doi T. Jang R.W. et al.

Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 Trial.

JAMA Oncol. 4: e180013Fuchs C.S. Ozguroglu M. Bang Y.J. et al.

Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial.

Gastric Cancer. 25: 197-206Kang Y.K. Boku N. Satoh T. et al.

Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Lancet. 390: 2461-2471Yoon H.H. Shi Q. Sukov W.R. et al.

Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma.

J Clin Oncol. 30: 3932-3938Gowryshankar A. Nagaraja V. Eslick G.D.

HER2 status in Barrett's esophagus & esophageal cancer: a meta analysis.

J Gastrointest Oncol. 5: 25-35Koopman T. Smits M.M. Louwen M. et al.

HER2 positivity in gastric and esophageal adenocarcinoma: clinicopathological analysis and comparison.

J Cancer Res Clin Oncol. 141: 1343-1351Plum P.S. Gebauer F. Kramer M. et al.

HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma.

BMC Cancer. 19: 38Bartley A.N. Washington M.K. Colasacco C. et al.

HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the college of american pathologists, american society for clinical pathology, and the american society of clinical oncology.

J Clin Oncol. 35: 446-464Bang Y.J. Van Cutsem E. Feyereislova A. et al.

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Lancet. 376: 687-697Park S. Jiang Z. Mortenson E.D. et al.

The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity.

Cancer Cell. 18: 160-170Gall V.A. Philips A.V. Qiao N. et al.

Trastuzumab increases HER2 uptake and cross-presentation by dendritic cells.

Cancer Res. 77: 5374-5383Taylor C. Hershman D. Shah N. et al.

Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy.

Clin Cancer Res. 13: 5133-5143Chaganty B.K.R. Qiu S. Gest A. et al.

Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNgamma secretion.

Cancer Lett. 430: 47-56Janjigian Y.Y. Maron S.B. Chatila W.K. et al.

First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial.

Lancet Oncol. 21: 821-831Rha S.Y. Lee C-.K. Kim H.S. et al.

A multi-institutional phase Ib/II trial of first-line triplet regimen (Pembrolizumab, Trastuzumab, Chemotherapy) for HER2-positive advanced gastric and gastroesophageal junction cancer (PANTHERA Trial): Molecular profiling and clinical update.

J Clin Oncol. 39: 218Janjigian Y.Y. Kawazoe A. Yanez P. et al.

The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer.

Nature. 600: 727-730Meric-Bernstam F. Hamilton E.P. Beeram M. et al.

Zanidatamab (ZW25) in HER2-expressing gastroesophageal adenocarcinoma (GEA): Results from a phase I study.

J Clin Oncol. 39: 164Makiyama A. Sukawa Y. Kashiwada T. et al.

Randomized, phase II study of trastuzumab beyond progression in patients with HER2-positive advanced gastric or gastroesophageal junction cancer: WJOG7112G (T-ACT Study).

J Clin Oncol. 38: 1919-1927Satoh T. Xu R.H. Chung H.C. et al.

Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study.

J Clin Oncol. 32: 2039-2049Thuss-Patience P.C. Shah M.A. Ohtsu A. et al.

Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study.

Lancet Oncol. 18: 640-653Seo S. Ryu M.H. Park Y.S. et al.

Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3).

Gastric Cancer. 22: 527-535Pietrantonio F. Caporale M. Morano F. et al.

HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research.

Int J Cancer. 139: 2859-2864Ogitani Y. Hagihara K. Oitate M. et al.

Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity.

Cancer Sci. 107: 1039-1046Shitara K. Bang Y.J. Iwasa S. et al.

Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer.

N Engl J Med. 382: 2419-2430Cutsem E.V. Di Bartolomeo M. Smyth E. et al.

Primary analysis of a phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after a trastuzumab-containing regimen.

Ann Oncol. 21: S1283-S1346Doki Y. Ajani J.A. Kato K. et al.

Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma.

N Engl J Med. 386: 449-462Leone A.G. Petrelli F. Ghidini A. et al.

Efficacy and activity of PD-1 blockade in patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis with focus on the value of PD-L1 combined positive score.

ESMO Open. 7: 100380Luo H. Lu J. Bai Y. et al.

Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial.

JAMA. 326: 916-925Shen L. Lu Z. Wang J. et al.

Sintilimab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced or metastatic esophageal squamous cell cancer: First results of the phase III ORIENT-15 study.

Ann Oncol. 32: S1283-S1346Wang Z.X. Cui C. Yao J. et al.

Toripalimab plus chemotherapy in treatment-naive, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial.

Cancer Cell. 40: 277-288 e273Kato K. Cho B.C. Takahashi M. et al.

Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.

Lancet Oncol. 20: 1506-1517Huang J. Xu J. Chen Y. et al.

Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study.

Lancet Oncol. 21: 832-842Shen L. Kato K. Kim S-.B. et al.

RATIONALE 302: Randomized, phase 3 study of tislelizumab versus chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma.

J Clin Oncol. 39 ()van Hagen P. Hulshof M.C. van Lanschot J.J. et al.

Preoperative chemoradiotherapy for esophageal or junctional cancer.

N Engl J Med. 366: 2074-2084Goodman K.A. Ou F.S. Hall N.C. et al.

Randomized phase II Study of PET response-adapted combined modality therapy for esophageal cancer: mature results of the CALGB 80803 (Alliance) trial.

J Clin Oncol. 39: 2803-2815Rozeman E.A. Menzies A.M. van Akkooi A.C.J. et al.

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.

Lancet Oncol. 20: 948-960Janjigian Y.Y. Wolchok J.D. Ariyan C.E.

Eradicating micrometastases with immune checkpoint blockade: Strike while the iron is hot.

Cancer Cell. 39: 738-742Klempner S.J. Lee K-.W. Metges J-.P. et al.

Phase 2 study of zolbetuximab plus mFOLFOX6 in claudin 18.2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ): ILUSTRO cohort 2.

J Clin Oncol. 39: e16063Deng N. Goh L.K. Wang H. et al.

A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets.

Gut. 61: 673-684Klempner S.J. Madison R. Pujara V. et al.

FGFR2-Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape.

Oncologist. 24: 1462-1468Wainberg Z.A. Enzinger P.C. Kang Y-.K. et al.

Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT).

J Clin Oncol. 39: 160Wang K.L. Wu T.T. Choi I.S. et al.

Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome.

Cancer. 109: 658-667Maron S.B. Alpert L. Kwak H.A. et al.

Targeted therapies for targeted populations: anti-EGFR treatment for EGFR-amplified gastroesophageal adenocarcinoma.

Cancer Discov. 8: 696-713Petty R.D. Dahle-Smith A. Stevenson D.A.J. et al.

Gefitinib and EGFR gene copy number aberrations in esophageal cancer.

J Clin Oncol. 35: 2279-2287Lordick F. Kang Y-.K. Salman P. et al.

Clinical coutcome according to tumor HER2 status and EGFR expression in advanced gastric cancer patients from the EXPAND study.

J Clin Oncol. 31: 4021Maron S.B. Moya S. Morano F. et al.

Epidermal growth factor receptor inhibition in epidermal growth factor receptor-amplified gastroesophageal cancer: retrospective global experience.

J Clin Oncol. 40: 2458-2467Sanchez-Vega F. Hechtman J.F. Castel P. et al.

EGFR and MET amplifications determine response to HER2 inhibition in ERBB2-amplified esophagogastric cancer.

Cancer Discov. 9: 199-209Ott P.A. Hodi F.S. Buchbinder E.I.

Inhibition of immune checkpoints and vascular endothelial growth factor as combination therapy for metastatic melanoma: an overview of rationale, preclinical evidence, and initial clinical data.

Front Oncol. 5: 202Doleschel D. Hoff S. Koletnik S. et al.

Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth.

J Exp Clin Cancer Res. 40: 288Nakajima T.E. Kadowaki S. Minashi K. et al.

Multicenter phase I/II study of nivolumab combined with paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer.

Clin Cancer Res. 27: 1029-1036Fukuoka S. Hara H. Takahashi N. et al.

Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase Ib trial (REGONIVO, EPOC1603).

J Clin Oncol. 38: 2053-2061